

EXHIBIT INDEX

- Exhibit 1 – GSK performance-based sales incentive: “The Strongest Link: Special Incentive Program for Wellbutrin SR”
- Exhibit 2 – GSK slides providing performance update, market research and 2002 plan of action for Wellbutrin SR
- Exhibit 3 – GSK slides: “Perceptions and Definition of Antidepressant Efficacy Among PCPs, January 6, 2000”
- Exhibit 4 – GSK slides: “Market Landscape Study: Wellbutrin SR, October 6, 2000”
- Exhibit 5 – GSK sales training slides: “Wellbutrin SR® Operation Hustle Meeting,” May 10-18, 1999
- Exhibit 6 – GSK sales training material: “Insights on Neurotransmitters, August 2000”
- Exhibit 7 – GSK sales training material: “Use of Wellbutrin SR® for the Treatment of Anxiety-Related Disorders, February 4, 2002”
- Exhibit 8 – GSK sales training material: “Advances in the Treatment of Depression”
- Exhibit 9 – GSK sales training material comparing Wellbutrin SR to its “competition”
- Exhibit 10 – Newsweek article, “How it all Starts Inside Your Brain,” as distributed to Wellbutrin field sales teams
- Exhibit 11 – Slide set: “The Theoretical Role of Dopamine and Norepinephrine in Human Behavior” developed by Dr. Jim Hudziak
- Exhibit 12 – GSK sales training material: “Neurotransmitter and Receptor Pharmacology”
- Exhibit 13 – GSK slides: “Wellbutrin SR: Strategic Plan, April 27, 2000”
- Exhibit 14 – A. Clayton and J. Pradko, “The Prevalence of Sexual Dysfunction Among New-Generation Antidepressants”
- Exhibit 15 – R. Phillips and J. Slaughter, “Depression and Sexual Desire” as distributed to GSK Wellbutrin field sales teams
- Exhibit 16 – GSK sales training slides: “Responding to Physician Questions about Prevalence of Sexual Dysfunction”
- Exhibit 17 – GSK slides: “2002 Strategy Plan for Wellbutrin SR”

Exhibit 18 – Wellbutrin Faxback: “Effects of Wellbutrin SR® on Body Weight”

Exhibit 19 – Glaxo-funded study: “Bupropion SR in Obesity: A Randomized Double-Blind Placebo-Controlled Study”

Exhibit 20 – GSK memo re: “New Data on Weight” and attachment

Exhibit 21 – “National Speak Training Agenda and Faculty for Wellbutrin SR® December 6-7, 2001”

Exhibit 22 – GSK memo re: “New Data on Weight” and attachment

Exhibit 23 – “Wellbutrin XL Clinical Program Outline” revised May 16, 2002

Exhibit 24 – GSK 2003 “Plan of Action” presentation slides showing Wellbutrin’s annual revenue growth

Exhibit 25 – 2003 Wellbutrin “Operating Plan”

Exhibit 26 – Wellbutrin SR Memo re: “P.R.I.D.E 2001 Program Roll-out”

Exhibit 27 – GSK slide: “2003 PRIDE Rationale & Objectives”

Exhibit 28 – “PRIDE Program Schedule – Wellbutrin SR”

Exhibit 29 – “Pradko - Hudziak - Green Program Schedule - Wellbutrin SR”

Exhibit 30 – GSK memo re: “P.R.I.D.E 2002 Teleconferences - May & June”

Exhibit 31 – Email exchange re: “PRIDE Teleconference Slides”

Exhibit 32 – PRIDE Thought Leader Teleconference schedule. February - March 2003

Exhibit 33 – GSK speaker allocations

Exhibit 34 – “Wellbutrin 2003 Teleconference Schedule”

Exhibit 35 – List of GSK’s approved Wellbutrin PRIDE speakers for 2001

Exhibit 36 – GSK memo re: “2003 PRIDE Binder”

Exhibit 37 – PRIDE Binder table of contents

Exhibit 38 – SCS PRIDE program summary

Exhibit 39 – “Wellbutrin SR: Depression Programming” listing product speakers by date

Exhibit 40 – GSK invitation to attend a December 2001 PRIDE event

Exhibit 43 – “Speaker Training Meeting for Wellbutrin SR®” Agenda for January 26-28, 2001, showing Dr. Pradko as a speaker

- Exhibit 44 – Email conversation re: “Wellbutrin Teleconference & PRIDE Report(s),” May 31, 2002
- Exhibit 45 - Outline from GSK speaker Dr. James Pradko’s presentation “Neuroreceptor Basis of Initial Antidepressant Choice”
- Exhibit 46 – Slides from GSK speaker Dr. James Pradko’s February 28, 2002 presentation of “Neuroreceptor Basis of Initial Antidepressant Choice”
- Exhibit 47 – Slides from GSK speaker Dr. James Pradko’s April 21, 2002 presentation of “Neuroreceptor Basis of Initial Antidepressant Choice”
- Exhibit 48 – Slides from GSK speaker Dr. James Pradko’s July 26, 2002 presentation of “Neuroreceptor Basis of Initial Antidepressant Choice”
- Exhibit 49 – Slides from GSK speaker Dr. James Pradko’s August 26, 2002 presentation of “Neuroreceptor Basis of Initial Antidepressant Choice”
- Exhibit 50 – GSK email exchange re: “Key Points from Dr. Hudziak Program,” August 27, 2002.
- Exhibit 51 – Slides from GSK speaker Dr. Jim Hudziak’s presentation “The Theoretical Role of Dopamine and Norepinephrine in Human Behavior”
- Exhibit 52 – Slides from GSK speaker Dr. Jim Hudziak’s presentation “The Theoretical role of Serotonin, Norepinephrine and Dopamine in Human Behavior”
- Exhibit 53 – Slides from GSK speaker Dr. Jim Hudziak’s presentation “Novel Approaches to the Selection of Antidepressants”
- Exhibit 54 – Email exchange re: “Key Points from Dr. Hudziak program”
- Exhibit 55 – Outline of GSK speaker Dr. Norman Sussman’s September 20, 2002 PRIDE presentation
- Exhibit 56 – Email exchange and summary of a PRIDE event at which GSK speaker Dr. Sarah Atkinson presented
- Exhibit 57 – Slides from GSK speaker Dr. Anita Clayton’s presentation “The Impact Antidepressants have on Sexual Function and Weight”
- Exhibit 58 – Slides from a presentation titled “Matching the Treatment to the Patient”
- Exhibit 59 – GSK email forwarding notes from Dr. Sarah Atkinson’s PRIDE presentation “Mood Disorders in Complex Patients & Overlapping Disorders”
- Exhibit 60 – GSK email exchange regarding a PRIDE presentation by Dr. Sarah Atkinson
- Exhibit 61 – Slides from GSK speaker Dr. Jeffery Green’s November 1, 2001 presentation “Current Issues in Antidepressant Selection”

- Exhibit 62 – Slides from GSK speaker Dr. Jeffery Green’s October 29, 2002 presentation “Current Issues in Antidepressant Selection”
- Exhibit 63 – Slides from GSK speaker Dr. James Pradko’s presentation “Neuroreceptor Basis of Initial Antidepressant Choice” with advertisement for audio recording of lecture
- Exhibit 64 – GSK memo re and slides from GSK speaker Dr. James Pradko’s March 5, 2000 presentation of “Neuroreceptor Basis of Initial Antidepressant Choice”
- Exhibit 65 – “Wonderful Wellbutrin?” article describing Wellbutrin’s sex-enhancing effects, as distributed to Wellbutrin field sales teams
- Exhibit 66 – GSK memo re: “New Data on Weight,” June 27, 2001
- Exhibit 67 – GSK slides: “Effects of Wellbutrin SR® on Body Weight”
- Exhibit 68 – Slides from GSK speaker Dr. Ken Fujoka’s presentation “Effects of Bupropion SR on Body Weight
- Exhibit 69 – Slides from a presentation titled “Effects of Wellbutrin SR® (bupropion HCl) Sustained-Release tablets on Body Weight
- Exhibit 70 – Kishore M. Gadde, et al., “Bupropion for Weight Loss: An Investigation of Efficacy and Tolerability in Overweight and Obese Women
- Exhibit 71 – Adesh K. Jain, et al., “A Study of Bupropion SR compared to Placebo in Obese Adults with Mild to Moderate Depressive Symptoms”
- Exhibit 72 – Results from a Glaxo supported study showing “Bupropion SR Significantly Enhances Weight Loss When Used With a Moderate-Intensity Lifestyle Intervention”
- Exhibit 73 – Gade KM. Parker CB, Maner LG et al., “Bupropion for Weight Loss: An investigation of Efficacy and tolerability in Overweight and Obese Women”
- Exhibit 74 – GSK Faxback titled “Effects of Wellbutrin SR® on Body Weight”
- Exhibit 75 – Slides from a presentation titled “Effects of Wellbutrin SR® (bupropion HCl) Sustained-Release Tablets on Body Weight”
- Exhibit 76 – GSK slides: “Bupropion SR for Weight Loss: Combination with SlimFast & Exercise”
- Exhibit 77 – Slides from a presentation titled “Effects of Wellbutrin SR® on Body Weight”
- Exhibit 78 – GSK faxback titled “effects of Wellbutrin SR® on Body Weight,” February 4, 2002
- Exhibit 79 – Slides from a presentation titled “Effects of Wellbutrin SR® (bupropion HCl) sustained-Release Tablets on Body Weight”

- Exhibit 80 – GSK faxback titled “Effects of Wellbutrin SR® on Body Weight”
- Exhibit 81 – Slides from Dr. Adam Keller Ashton’s presentation titled “Decision Making When Managing Antidepressant-Induced Side Effects”
- Exhibit 82 – Slides from a presentation: “Effects of Wellbutrin SR® (bupropion HCl) Sustained-Release Tablets on Body Weight
- Exhibit 83 – GSK “Knowledge Certification” scenarios including off-label Wellbutrin weight data
- Exhibit 84 – GSK Wellbutrin SR® Knowledge Certification evaluation form
- Exhibit 85 – Evaluation form for testing GSK sales rep’s knowledge of Wellbutrin’s off-label treatment of ADHD
- Exhibit 87 – GSK slides from “2003 Wellbutrin XL Operating Plan”
- Exhibit 88 – GSK operating plan – Activity Phasing Overview
- Exhibit 89 – GSK training slides: “Verbalization Review for Valtrex®”
- Exhibit 90 – GSK marketing slides: “Semester I Managers Meeting POA and Update: Valtrex”
- Exhibit 91 – GSK sponsored study: “Tomorrow’s challenges for Herpesvirus Management: Potential Application of Valacyclovir”
- Exhibit 92 – GSK training module, “Oral Herpes”
- Exhibit 93 – GSK memo re: “Top 25 Honoraria and Grant Recipients”
- Exhibit 94 – GSK’s top ten speakers by product
- Exhibit 95 – Valtrex “Monthly NRX – Growth Trac”
- Exhibit 96 – GSK’s Peer Discussion Budget, November 2002
- Exhibit 97 – “Lamictal Neurology National Speaker List”
- Exhibit 98 – Advair Product Information as published August 2000
- Exhibit 99 – Excerpt from GSK Commercial Practices Policies Resource Manual
- Exhibit 100 – Advair “Leader Guide: Elion Workshops- Semester I, ‘03”
- Exhibit 101 – Advair Diskus “Selling Resource- Semester I -2003”
- Exhibit 102 – Howard Friedman et al., “A Retrospective Study of the Use of Fluticasone Propionate/Salmeterol Combination as Initial Asthma controller Therapy in a Commercially Insured Population”

Exhibit 103 – Transcript: Glaxo-Wellcome presentation of Advair Diskus to the FDA Pulmonary and Allergy Drugs Advisory Committee on November 23, 1999

Exhibit 104 – Medical Officer Review of Advair dated January 24, 2000

Exhibit 105 – GSK PowerPoint titled “Asthma Semester II, 2002”

Exhibit 106 – GSK PowerPoint titled “Asthma Promotion 2003 Operating Plan”

Exhibit 107 – Advair marketing materials: “Promise Program”

Exhibit 108 – GSK-sponsored “Calhoun study”

Exhibit 109 – GSK-sponsored “Kavuru study”

Exhibit 110 – Advair sales training material: “Advair Selling Resource – Semester II—2003”

Exhibit 111 – Advair sales training material: “Advair Selling Resource – Semester I—2003”

Exhibit 112 – Advair sales training material: “Promotional Cycle II- 2004”

Exhibit 113 – GSK-designed “Fuhlbrigge survey”

Exhibit 114 – GSK slides: “Asthma Promotion 2003 Operating Plan”

Exhibit 115 – Advair marketing materials

Exhibit 116 – NIH guidelines for the diagnosis and management of asthma

Exhibit 117 – HHS/NIH 2007 Summary Report: “Guidelines for the Diagnosis and Management of Asthma”

Exhibit 118 – Advair product information as published in 2003

Exhibit 119 – Advair product information as published in 2006

Exhibit 120 – GSK sales training material: “Steroid Sparing Effects of Serevent®”

Exhibit 121 – A. McIvor et al., “Potential Masking Effects of Salmeterol on Airway Inflammation in Asthma”

Exhibit 123 – GSK letter advising that corticosteroids should not be reduced when salmeterol is initiated

Exhibit 124 – Advair sales training material: “Learning System for Advair Diskus®—Unit 3 – Selling Advair Diskus”

Exhibit 125 – FDA-imposed “Risk Management Plan”

Exhibit 126 – Advair Diskus® medical officer review (2003)

Exhibit 127 – Flovent Diskus and Advair Diskus 2002 clinical team leader review memorandum (2002)

Exhibit 128 – GSK-sponsored article misrepresenting side effects of Advair 500

Exhibit 129 – GSK-sponsored article misrepresenting side effects of Advair 500

Exhibit 130 – GSK faxback incorporating misleading Advair 500 safety information

Exhibit 131 – GSK faxback incorporating misleading Flovent safety information

Exhibit 132 – GSK CME “Building a COPD Care Plan”

Exhibit 133 – GSK sales training material titled “COPD Market Development Selling Resource – Semester II- 2002”

Exhibit 134 – Advair Diskus® Medical Officer Review (2003)

Exhibit 135 – GSK “TORCH” study investigating Advair 500 and mortality in COPD patients

Exhibit 136 – GSK Investor Relations slides delivered by Stan Hull in December 2006

Exhibit 137 – GSK Investor Relations slides delivered by Stan Hull in June 2006

Exhibit 138 – GSK Investor Relations slides delivered in February 2007

Exhibit 139 – GSK Investor Relations slides titled “3Q Results 2006” listing TORCH as a near-term growth opportunity

Exhibit 140 – GSK slides showing Advair 500 sales as the fastest growing of any Advair prescription strength

Exhibit 141 – GSK slides providing “Northeast Regional Overview” of penetration of GSK prescription drugs

Exhibit 142 – Imitrex Injection- product information (2001)

Exhibit 143 – Imitrex Nasal Spray- product information (2001)

Exhibit 144 – Imitrex tablets- product information (2000)

Exhibit 145 – “Migraine Strategic Plan Review – 2000-2004”

Exhibit 146 – GSK PowerPoint “Migraine Brand Review” describes “expanding the diagnosis” for migraine care

Exhibit 147 – GSK CNS sales materials

Exhibit 148 – GSK Imitrex sales material using expanded definition of “migraine”

Exhibit 149 – GSK marketing presentation, “One Nerve Network – Multiple Presentations of Migraine,” stating that “Rigid adherence to HIS criteria in diagnosing migraine may result in underdiagnoses of migraine”

Exhibit 150 – Imitrex marketing material listing “migraine myths”

Exhibit 151 – GSK marketing material: “Is it really a tension headache? Take a closer look”

Exhibit 152 – GSK selling resource suggesting that every headache of a migrianeur is a migraine and could be treated with Imitrex

Exhibit 153 – GSK marketing material: “Physician Diagnosed and Patient Self-Described “Sinus Headache” is Predominately Migraine”

Exhibit 154 – GSK promotional publication: “Issues in Headache Management,” February 2003

Exhibit 155 – GSK promotional materials: “Is it really sinus headache? Take a closer look”

Exhibit 156 – GSK promotional materials explaining “Placebo-controlled Study – Migraine patients with self-described ‘sinus headache’”

Exhibit 157 – GSK promotional handout: “A Guide to Understanding Your Migraine”

Exhibit 158 – GSK promotional slides: “Early Intervention with Imitrex® (sumatriptan succinate) in the Treatment of a Migraine Attack”

Exhibit 159 – GSK sales training materials: “Central Nervous System Selling Resource, Semester II-2001”

Exhibit 160 – GSK documents tracking physician programs and spending in DE County

Exhibit 161 – GSK documents tracking physician programs and spending in Cherry Hill

Exhibit 162 - GSK documents tracking physician programs and spending in Wilmington

Exhibit 163 – GSK sales training slides “New GSK Targeting,” April 2002

Exhibit 164 – Documentation of GSK payments to Dr. Jeffrey Green

Exhibit 165 – Documentation of GSK payments to Dr. Troy Thompson

Exhibit 166 – Documentation of GSK payments to Dr. Troy Thompson

Exhibit 167 – Documentation of GSK payments to Dr. James Pradko

Exhibit 168 – Documentation of GSK payments to Dr. James Pradko

Exhibit 169 – Documentation of GSK payments to Dr. Matthew Pitera

Exhibit 170 – Documentation of GSK payments to Dr. Timothy Smith

Exhibit 171 – Documentation of GSK payments to Dr. James Pradko

Exhibit 172 – Documentation of GSK payments to physician advisory board speakers

Exhibit 173 – Documentation of GSK payments to Dr. James Pradko

Exhibit 174 – Documentation of GSK payments to Dr. Matthew Pitera

Exhibit 175 – Documentation of GSK payments to Dr. James Hudziak

Exhibit 176 – Documentation of GSK payments to Dr. James Hudziak

Exhibit 177 – Documentation of GSK payments to Dr. James Hudziak

Exhibit 178 – Documentation of GSK payments to Dr. James Pradko

Exhibit 179 – Documentation of GSK payments to Dr. James Pradko

Exhibit 180 – Documentation of GSK payments to Dr. James Pradko

Exhibit 181 – Documentation of GSK payments to Dr. James Hudziak

Exhibit 182 – Documentation of GSK payments to Dr. James Hudziak

Exhibit 183 – Documentation of GSK payments to Dr. James Hudziak

Exhibit 184 – Documentation of GSK payments to Dr. Norman Sussman

Exhibit 185 – Documentation of GSK payments to Dr. Jeffrey Green

Exhibit 186 – Documentation of GSK payments to Dr. B. Kenneth Nelson

Exhibit 187 – Documentation of GSK payments to Dr. James Pradko

Exhibit 188 – Documentation of GSK payments to Dr. Jeffrey Green

Exhibit 189 – Documentation of GSK payments to Dr. James Pradko

Exhibit 190 – Documentation of GSK payments to Dr. James Hudziak

Exhibit 191 – Documentation of GSK payments to Dr. James Hudziak

Exhibit 192 – Documentation of GSK payments to Dr. James Hudziak

Exhibit 193 – Documentation of GSK payments to Dr. James Pradko

Exhibit 194 – Documentation of GSK payments to Dr. James Hudziak

Exhibit 195 – GSK Special Issue Boards Schedule

Exhibit 196 – GSK slides evaluating luxury boxes and season tickets expenses

Exhibit 197 – GSK documents tracking physician programs and spending in Harrisburg

Exhibit 198 – GSK documents tracking physician programs and spending in Lancaster

Exhibit 199 – GSK documents tracking physician programs and spending in West Chester

Exhibit 200 – GSK documents tracking physician programs and spending in Camp Hill

Exhibit 201 – Outline from GSK speaker Dr. Sarah Atkinson’s presentation on mood disorders

Exhibit 202 – GSK physician tutorial schedule

Exhibit 203 – GSK documents tracking physician programs and spending in Roxborough

Exhibit 205 – GSK documents tracking physician programs and spending in Lehigh Valley

Exhibit 206 – GSK email exchange Re “Grant Request for Dr. London,” May 9, 2002

Exhibit 207 – GSK email exchange Re “WSR Materials,” May 24, 2002

Exhibit 208 – GSK email exchange Re “Profiles and Depression – CME,” July 16, 2002

Exhibit 209 – GSK slides explaining 2002 Imitrex marketing and speaker programs

Exhibit 210 – Letter confirming James Pradko’s GSK speaking commitments

Exhibit 211 – GSK’s Top Ten speakers by product

Exhibit 212 – GSK email exchange re: “Dr. Sussman’s Buffalo Programs on 9-20-02,” August 7, 200